Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Carparts.Com Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Carparts.Com Inc trades at $5.87 (market cap $47.94M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 832.1× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PRTS | |
|---|---|---|
Market Cap | $39.89B | $47.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $11.40 |
52-Week Low | $278.09 | $3.88 |
Enterprise Value | $38.15B | $62.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
PRTS trades at $5.87, down 1.92% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $50.44 million in 2025, though recent quarters have beaten EPS estimates. A recent reverse stock split and new credit facility aim to stabilize operations amid declining revenue trends from $676 million in 2023 to $548 million in 2025.
The outlook remains challenging with persistent losses and negative cash flow, but analyst consensus is positive with 60% buy ratings. Key risks include sustained unprofitability and competitive pressures, while potential upside hinges on cost control and execution of strategic initiatives to return to growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
